Quick Answer
Compass Therapeutics, Inc. reported Stockholders Equity of $196.79 million for fiscal year 2025.
Compass Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $196.79M | +57.1% |
| 2024 | $125.23M | -15.7% |
| 2023 | $148.54M | -18.2% |
| 2022 | $181.64M | +29.7% |
| 2021 | $140.08M | +250.7% |
| 2020 | $39.95M | +37061.5% |
| 2020 | -$108.1K | -101.0% |
| 2019 | $11.27M | +16061.4% |
| 2019 | -$70.6K | +99.9% |
| 2018 | -$84.77M | -245251.9% |
| 2018 | -$34.6K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $209.61M | +51.5% | +124.9% |
| June 30, 2025 | $93.21M | -36.2% | -15.5% |
| March 31, 2025 | $110.28M | -29.8% | -11.9% |
| December 31, 2024 | $125.23M | -15.7% | -9.5% |
| September 30, 2024 | $138.40M | -13.5% | -5.3% |
| June 30, 2024 | $146.10M | -13.2% | -7.0% |
| March 31, 2024 | $157.06M | -10.4% | +5.7% |
| December 31, 2023 | $148.54M | -18.2% | -7.2% |
- Compass Therapeutics, Inc. showed an increase of +57.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Compass Therapeutics, Inc.’s stockholders equity has grown by 569650.2% (from -$34.6 thousand to $196.79 million).
- The most recent figure is from Compass Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: